Proof-of-concept trial on the efficacy of sodium tungstate in human obesity

Diabetes, Obesity and Metabolism

Volumn 12, Issue 11, 2010, Pages 1013-1018

  Hanzu, F ^a,b   Gomis, R ^a,b   Coves, M J ^a,b   Viaplana, J ^a,b   Palomo, M ^a   Andreu, A ^a   Szpunar, J ^c   Vidal, J ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Laboratoire de Chimie Analytique Bio Inorganique et Environnement   (France)

Author keywords

Antiobesity drug; Clinical trial; Phase I and II study

Indexed keywords

ANTILIPEMIC AGENT; PLACEBO; TUNGSTATE SODIUM; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY FAT; BODY MASS; BODY WEIGHT; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY EXPENDITURE; FEMALE; GASTROINTESTINAL DISEASE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MALE; OBESITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYNCOPE; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION;

EID: 77957269135     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01293.x     Document Type: Article

References (18)

1. James WP. WHO recognition of the global obesity epidemic. Int J Obes (Lond) 2008, 32((Suppl. 7)):S120-S126..
2. Cai L, Lubitz J, Flegal KM, Pamuk ER. The predicted effects of chronic obesity in middle age on medicare costs and mortality. Med Care 2010, 48:510-517..
3. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194-1199..
4. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000, 404:661-671..
5. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008, 70:537-556..
6. Zelissen PM, Stenlof K, Lean ME. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab 2005, 7:755-761..
7. Claret M, Corominola H, Canals I. Tungstate decreases weight gain and adiposity in obese rats through increased thermogenesis and lipid oxidation. Endocrinology 2005, 146:4362-4369..
8. Canals I, Carmona MC, Amigó M. A functional leptin system is essential for sodium tungstate antiobesity action. Endocrinology 2009, 150:642-650..
9. Lison D, Buchet JP, Hoet P. Toxicity of tungsten. Lancet 1997, 349:58-59..
10. Guidance for industry and reviewers. Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov, Food and Drug Administration., December 2002 (Draft Guidance). Available from URL:, Accessed February 2008.
11. Woywodt A, Blann AD, Kirsch T. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost 2006, 4:671-677..
12. Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin North Am 2010, 39:69-79.
13. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004, 3:CD004094..
14. Astrup A, Rössner S. Lessons from obesity management programmes: greater initial weight loss improves longterm maintenance. Obes Rev 2000, 1:17-19..
15. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006, 8:206-213..
16. Toplak H, Ziegler O, Keller U. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005, 7:699-708..
17. O'Rahilly S, Farooqi IS. Human obesity as a heritable disorder of the central control of energy balance. Int J Obes (Lond) 2008, 32((Suppl. 7)):S55-S61..
18. Wadden TA, Berkowitz RI, Womble LG. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005, 353:2111-2120..